Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Eli Lilly and Novo Nordisk dominate the GLP-1 market, and most payers secure access through competitive rebate contracts, offering discounts of 35%-50%
The epidemiology of nonalcoholic fatty liver disease: a global perspective
C.SansomM
Semaglutide works through GLP-1 receptor activation and has a well-established track record with broad real-world availability
US$ 25.24
US$ 24.37
US$ 25.47
US$ 24.73
US$ 21.16
US$ 29.21
US$ 29.82
US$ 21.19
US$ 28.89
US$ 27.54
US$ 24.82
US$ 26.78
